Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  OTC Bulletin Board - Other OTC  >  Vycor Medical, Inc.    VYCO

VYCOR MEDICAL, INC.

(VYCO)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancials 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

VYCOR MEDICAL INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

share with twitter share with LinkedIn share with facebook
06/30/2020 | 05:08pm EDT

Item 7.01 Regulation FD Disclosure

On June 30, 2020, Vycor Medical, Inc. (the "Company") published a press release entitled "Vycor Medical, Inc. Agrees New NovaVision Licensing Agreement" announcing a new licensing arrangement with respect to Germany, Austria and Switzerland with HelferApp GmbH.

The information in Item 7.01 of this report, including Exhibit 99.1, is being furnished pursuant to Item 7.01 of Form 8-K and shall be deemed "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended.

Item 9.01 Financial Statements and Exhibits




(d) Exhibits:



Exhibit No.   Description
99.1            Vycor Medical, Inc. Press Release dated June 30, 2020

© Edgar Online, source Glimpses

share with twitter share with LinkedIn share with facebook
Latest news on VYCOR MEDICAL, INC.
06/30VYCOR MEDICAL INC : Regulation FD Disclosure, Financial Statements and Exhibits ..
AQ
06/30Vycor Medical, Inc. Agrees New NovaVision Licensing Agreement
GL
05/12VYCOR MEDICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
03/27VYCOR MEDICAL INC : Change in Directors or Principal Officers, Results of Operat..
AQ
03/27Vycor Medical Reports Financial Results for the year ended December 31st, 201..
GL
03/27VYCOR MEDICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
02/27VYCOR MEDICAL : New Study Shows Vision Rehab Treatment Effective for Stroke and ..
AQ
02/26VYCOR MEDICAL : Treatment for blindness successful in largest ever study
AQ
2019VYCOR MEDICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
2019VYCOR MEDICAL : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
More news
Financials (USD)
Sales 2019 1,48 M - -
Net income 2019 -0,80 M - -
Net Debt 2019 0,51 M - -
P/E ratio 2019 -2,96x
Yield 2019 -
Capitalization 6,20 M 6,20 M -
EV / Sales 2018 1,51x
EV / Sales 2019 2,66x
Nbr of Employees 9
Free-Float 33,3%
Chart VYCOR MEDICAL, INC.
Duration : Period :
Vycor Medical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers
NameTitle
Peter C. Zachariou Chief Executive Officer, Director & EVP
David Marc Cantor President & Director
Adrian Christopher Liddell Chairman, CFO & Principal Accounting Officer
Steven Girgenti Independent Director
Lowell M. Rush Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
VYCOR MEDICAL, INC.73.65%6
ABBOTT LABORATORIES15.91%178 257
MEDTRONIC PLC-14.21%130 549
BECTON, DICKINSON AND COMPANY4.31%83 917
BAXTER INTERNATIONAL INC.-0.55%42 098
DEXCOM, INC.102.83%41 700